AstraZeneca will buy U.S. biotech firm FibroGen's China unit for about $160 million, in its latest deal to boost its presence ...

The company, now based in North Beach, has lost more than $2 billion over 29 years. Its only approved drug, called roxadustat ...

Purchase price represents enterprise value of $85 million plus FibroGen net cash held in China at closing, currently estimated to be ...

H.C. Wainwright analyst Matthew Keller keeps a Buy rating on FibroGen (FGEN) with a $10 price target after the company announced the sale of ...

FibroGen sells its China unit to AstraZeneca for $160 million, extending its cash runway into 2027 and advancing its ...

FibroGen (NASDAQ:FGEN – Get Free Report) and Roche (OTCMKTS:RHHBY – Get Free Report) are both medical companies, but which is the better business? We will contrast the two businesses based on the ...

AstraZeneca is paying $160 million for FibroGen’s China business, giving the U.K.-based Big Pharma the regional rights to ...

The $160 million acquisition of a FibroGen subsidiary expands AstraZeneca’s foothold in China while the company works through ...

FibroGen (NASDAQ:FGEN – Get Free Report) is anticipated to post its earnings results before the market opens on Monday, February 24th. Analysts expect FibroGen to post earnings of ($0.14 ...

Investing.com -- FibroGen, Inc. (NASDAQ: FGEN)宣布将其中国子公司出售给阿斯利康制药 (NASDAQ: ...

周五，H.C. Wainwright维持对FibroGen（NASDAQ:FGEN）的"买入"评级，目标价保持在10.00美元不变。此前，FibroGen于2月20日宣布将其中国业务出售给阿斯利康制药，这一战略举措预计将显著提升公司财务稳定性并延长现金储备期。根据InvestingPro数据显示，该消息推动公司股价在过去六个月内大涨92.5%。

SAN FRANCISCO, Feb. 20, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced the sale of its China subsidiary to AstraZeneca for approximately $160 million. “Today, we ...